Meeting
2021 ASCO Annual Meeting
Plasma biomarker study of lenvatinib in gastroenteropancreatic neuroendocrine tumors reveals Ang2 and FGF2 as predictors of treatment response: Results from the international phase II TALENT trial (GETNE 1509).
Authors
Jaume Capdevila
Vall d’Hebron Institute of Oncology (VHIO), Medical Oncology, Vall d’Hebron University Hospital (HUVH), Barcelona, Spain
Jaume Capdevila , Gabriela Jimenez-Valerio , Alba Martinez , Jorge Hernando , Toni Ibrahim , Nicola Fazio , Carlos Lopez , Alex Teule , Juan W. Valle , Salvatore Tafuto , Ana B. Custodio , Nicholas Simon Reed , Markus Raderer , Enrique Grande , Rocio Garcia-Carbonero , Paula Jiménez-Fonseca , Vicente Alonso , Oriol Casanovas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Neuroendocrine/Carcinoid
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4113)
DOI
10.1200/JCO.2021.39.15_suppl.4113
Abstract #
4113
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
A phase II trial to assess the activity and safety of the hypoxia-activated prodrug evofosfamide (TH-302) in combination with sunitinib in patients with disseminated grade 1 and 2 pancreatic neuroendocrine tumors (pNET) as a first-line approach: The GETNE-1408 trial.
First Author: Enrique Grande
Poster
2019 ASCO Annual Meeting
Final results of the TALENT trial (GETNE1509): a prospective multicohort phase II study of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs).
First Author: Jaume Capdevila
Poster
2019 Gastrointestinal Cancers Symposium
Progression-free survival (PFS) and subgroups analyses of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs): Updated results from the phase II TALENT trial (GETNE 1509).
First Author: Jaume Capdevila
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Clinical development and evaluation of plasma angiogenesis factors from phase II study of FOLFIRI plus ramucirumab with recurrent colorectal cancer refractory to adjuvant chemotherapy with oxaliplatin/fluoropyrimidine (RAINCLOUD): RAINCLOUD-TR.
First Author: Tsuyoshi Hata